Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
Among 14 patients with prolactinomas a single injection of 50 mg bromocriptine in a retard preparation resulted in a decrease of the initially elevated serum prolactin levels (to 4-62% of the initial value) in 12 cases and in a tumor shrinkage in 9 patients. In 3 out of 4 acromegalics injection and/or infusion of the somatostatin analogue SMS 201-995 (in 2 patients with an implanted Infusaid pump) led to a normalization of growth hormone and somatomedin-C levels.
Schatz
H
H
Center of Internal Medicine, University of Giessen, FRG.
Stracke
H
H
Hildebrandt
G
G
D000172:Acromegaly / Q000188:drug therapy / Q000209:etiology; D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006728:Hormones / Q000097:blood; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011388:Prolactin / Q000097:blood / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D006728:Hormones; D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone; D015282:Octreotide